P251 THERAPEUTIC USE OF A CLINICAL STAGE CCR2 INHIBITOR, CCX872, IMPROVES OBESITY ASSOCIATED STEATOHEPATITIS IN MICE

2014 ◽  
Vol 60 (1) ◽  
pp. S149
Author(s):  
R. Parker ◽  
M.J. Walters ◽  
L. Ertle ◽  
K. Ebsworth ◽  
J. Tan ◽  
...  
2017 ◽  
Vol 114 (5) ◽  
pp. 944-949 ◽  
Author(s):  
Tushar Jain ◽  
Tingwan Sun ◽  
Stéphanie Durand ◽  
Amy Hall ◽  
Nga Rewa Houston ◽  
...  

Antibodies are a highly successful class of biological drugs, with over 50 such molecules approved for therapeutic use and hundreds more currently in clinical development. Improvements in technology for the discovery and optimization of high-potency antibodies have greatly increased the chances for finding binding molecules with desired biological properties; however, achieving drug-like properties at the same time is an additional requirement that is receiving increased attention. In this work, we attempt to quantify the historical limits of acceptability for multiple biophysical metrics of “developability.” Amino acid sequences from 137 antibodies in advanced clinical stages, including 48 approved for therapeutic use, were collected and used to construct isotype-matched IgG1 antibodies, which were then expressed in mammalian cells. The resulting material for each source antibody was evaluated in a dozen biophysical property assays. The distributions of the observed metrics are used to empirically define boundaries of drug-like behavior that can represent practical guidelines for future antibody drug candidates.


The Lancet ◽  
2014 ◽  
Vol 383 ◽  
pp. S78 ◽  
Author(s):  
Richard Parker ◽  
Matthew Walters ◽  
Linda Ertl ◽  
Karen Ebsworth ◽  
Joanne Tan ◽  
...  

2006 ◽  
Vol 175 (4S) ◽  
pp. 477-478 ◽  
Author(s):  
Kazuto Ito ◽  
Takumi Yamamoto ◽  
Hiroyuki Takechi ◽  
Kazuhiro Suzuki

2005 ◽  
Vol 173 (4S) ◽  
pp. 116-117
Author(s):  
Hannes Steiner ◽  
Reinhard Peschel ◽  
Tilko Müller ◽  
Christian Gozzi ◽  
Georg C. Bartsch ◽  
...  

1950 ◽  
Vol 34 (6) ◽  
pp. 1761-1777 ◽  
Author(s):  
Harold Jeghers ◽  
Irving B. Brick
Keyword(s):  

1993 ◽  
Vol 2 (2) ◽  
pp. 283-306
Author(s):  
John M. Flexner ◽  
Richard S. Stein ◽  
John P. Greer
Keyword(s):  

2001 ◽  
Vol 40 (4) ◽  
pp. 536-540 ◽  
Author(s):  
Finn Edler von Eyben ◽  
Ebbe Lindegaard Madsen ◽  
Ole Blaabjerg ◽  
Per Hyltoft Petersen ◽  
Hans von der Maase ◽  
...  

VASA ◽  
2002 ◽  
Vol 31 (1) ◽  
pp. 36-42 ◽  
Author(s):  
. Bucek ◽  
Hudak ◽  
Schnürer ◽  
Ahmadi ◽  
Wolfram ◽  
...  

Background: We investigated the long-term clinical results of percutaneous transluminal angioplasty (PTA) in patients with peripheral arterial occlusive disease (PAOD) and the influence of different parameters on the primary success rate, the rate of complications and the long-term outcome. Patients and methods: We reviewed clinical and hemodynamic follow-up data of 166 consecutive patients treated with PTA in 1987 in our department. Results: PTA improved the clinical situation in 79.4% of patients with iliac lesions and in 88.3% of patients with femoro-popliteal lesions. The clinical stage and ankle brachial index (ABI) post-interventional could be improved significantly (each P < 0,001), the same results were observed at the end of follow-up (each P < 0,001). Major complications occurred in 11 patients (6.6%). The rate of primary clinical long-term success for suprainguinal lesions was 55% and 38% after 5 and 10 years (femoro-popliteal 44% and 33%), respectively, the corresponding data for secondary clinical long-term success were 63% and 56% (60% and 55%). Older age (P = 0,017) and lower ABI pre-interventional (P = 0,019) significantly deteriorated primary clinical long-term success for suprainguinal lesions, while no factor could be identified influencing the outcome of femoro-popliteal lesions significantly. Conclusion: Besides an acceptable success rate with a low rate of severe complications, our results demonstrate favourable long-term clinical results of PTA in patients with PAOD.


Sign in / Sign up

Export Citation Format

Share Document